Trovagene is using RainDance Technologies' RainDrop Digital PCR system to develop and eventually run a cell-free transrenal BRAF mutation assay out of Trovagene's CLIA lab, the companies said this week.

San Diego-based Trovagene said last week that it had already validated the test, which detects BRAF mutations from cell-free DNA in urine, and said that it would be available sometime this quarter. However, the company did not disclose until this week that it was using the RainDrop system as the detection platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.